CeriBell (NASDAQ:CBLL) Major Shareholder Sells $4,071,644.16 in Stock

CeriBell, Inc. (NASDAQ:CBLL) major shareholder Tpg Gp A, Llc sold 202,368 shares of the business’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $20.12, for a total transaction of $4,071,644.16. Following the completion of the transaction, the insider owned 3,765,054 shares in the company, valued at $75,752,886.48. This represents a 5.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

CeriBell Stock Down 2.2%

Shares of NASDAQ:CBLL opened at $19.55 on Friday. The stock has a market capitalization of $741.73 million, a price-to-earnings ratio of -11.99 and a beta of 0.77. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $24.33. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44. The company’s fifty day moving average is $18.81 and its two-hundred day moving average is $19.72.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. The business had revenue of $26.49 million for the quarter, compared to analyst estimates of $26.09 million. Equities analysts anticipate that CeriBell, Inc. will post -1.69 EPS for the current year.

Institutional Investors Weigh In On CeriBell

Hedge funds have recently bought and sold shares of the company. Bank of America Corp DE lifted its stake in shares of CeriBell by 15.3% in the first quarter. Bank of America Corp DE now owns 319,837 shares of the company’s stock valued at $5,863,000 after buying an additional 42,340 shares during the period. Quantinno Capital Management LP boosted its position in CeriBell by 3.0% in the first quarter. Quantinno Capital Management LP now owns 140,347 shares of the company’s stock valued at $2,573,000 after buying an additional 4,119 shares in the last quarter. Sei Investments Co. grew its position in CeriBell by 2.3% during the 1st quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after acquiring an additional 1,125 shares during the last quarter. State of Wyoming bought a new stake in shares of CeriBell during the first quarter worth $62,000. Finally, KCM Capital Inc grew its holdings in CeriBell by 40.0% during the 1st quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock worth $25,662,000 after acquiring an additional 400,000 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on CBLL shares. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Canaccord Genuity Group reduced their target price on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, CeriBell has an average rating of “Moderate Buy” and an average target price of $22.20.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.